CHA2DS2-VASc Score Calculator

Clinical calculation support · Verify results before clinical use

Stroke Risk Assessment

Select each clinical characteristic. The score updates automatically.

0Score
C

Congestive heart failure / LV dysfunction

History of heart failure or objective evidence of left ventricular dysfunction.

+1 point
H

Hypertension

History of hypertension or treatment with antihypertensive medication.

+1 point
A₂

Age ≥75 years

Use this criterion for age 75 years or older. Do not also select the 65–74-year criterion.

+2 points
D

Diabetes mellitus

History of diabetes mellitus.

+1 point
S₂

Prior stroke, TIA, or systemic thromboembolism

Any previous event in this category.

+2 points
V

Vascular disease

Prior myocardial infarction, peripheral artery disease, or aortic plaque.

+1 point
A

Age 65–74 years

Select only if the patient is aged 65 to 74 years.

+1 point
Sc

Sex category

Female sex contributes 1 point in CHA₂DS₂-VASc, but is considered a risk modifier rather than an independent risk factor.

0 or +1 point
0CHA₂DS₂-VASc
Stroke risk assessment
Low estimated risk
No non-sex stroke risk factors selected.
Clinical interpretation

For patients with atrial fibrillation, assess individual thromboembolic risk and clinical context.

The absolute event rate associated with a given score varies among populations. This score supports, but does not replace, individualized clinical assessment and shared decision-making.

About the CHA₂DS₂-VASc Score

CHA₂DS₂-VASc is a clinical risk score used to estimate thromboembolic risk in patients with atrial fibrillation and to support decisions about oral anticoagulation. The maximum score is 9.

Variables and points

ComponentDefinitionPoints
CCongestive heart failure / LV dysfunction1
HHypertension1
A₂Age ≥75 years2
DDiabetes mellitus1
S₂Prior stroke, TIA, or thromboembolism2
VVascular disease1
AAge 65–74 years1
ScFemale sex category1

Interpreting the result

Under the 2023 ACC/AHA/ACCP/HRS guideline, oral anticoagulation is recommended when estimated annual thromboembolic risk is at least 2% (often corresponding to CHA₂DS₂-VASc ≥2 in men or ≥3 in women). It is reasonable to consider anticoagulation at an estimated risk of 1% to less than 2% (often corresponding to a score of 1 in men or 2 in women), using shared decision-making.

The 2024 ESC guideline uses CHA₂DS₂-VA, which excludes sex category: anticoagulation is recommended at a score ≥2 and should be considered at a score of 1. Use the guideline appropriate to your practice setting.

Clinical notes and references

Important limitations

  • Do not add both age categories: age ≥75 years scores 2 points and replaces the 65–74-year category.
  • Female sex alone does not generally justify anticoagulation in the absence of other stroke risk factors.
  • Do not use a single fixed annual stroke percentage for every score; observed event rates differ by cohort and clinical context.
  • Antiplatelet therapy is not a substitute for oral anticoagulation for stroke prevention in eligible patients with atrial fibrillation.
  • Mechanical heart valves and moderate-to-severe rheumatic mitral stenosis require a separate anticoagulation pathway; this calculator does not select an anticoagulant.

References

Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149:e1–e156. Guideline DOI: 10.1161/CIR.0000000000001193
Van Gelder IC, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2024;45:3314–3414. Guideline DOI: 10.1093/eurheartj/ehae176
Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263–272. DOI: 10.1378/chest.09-1584
Clinical disclaimer: This calculator is intended for clinical decision support in patients with atrial fibrillation. It does not replace clinical judgement, guideline review, assessment of bleeding risk, patient preferences, or evaluation of conditions that may alter anticoagulation decisions. Confirm all inputs before using the result.